false 0001492422 0001492422 2024-06-05 2024-06-05

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 5, 2024

 

 

Apellis Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-38276   27-1537290

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

100 Fifth Avenue

Waltham, MA

   02451
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 977-5700

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock   APLS   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 5.07.

Submission of Matters to a Vote of Security Holders.

Apellis Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 5, 2024. The following is a summary of the matters voted on at that meeting.

 

  (a)

The stockholders of the Company elected Paul Fonteyne and Stephanie Monaghan O’Brien as class I directors, each for a three-year term ending at the annual meeting of stockholders to be held in 2027. The results of the stockholders’ vote with respect to the election of the class I directors were as follows:

 

Name

    For      Withheld      Broker Non-Votes  

Paul Fonteyne

      98,837,712        5,320,270        5,506,458  

Stephanie Monaghan O’Brien

      80,481,023        23,672,152        5,511,264  

 

  (b)

The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The results of the stockholders’ vote with respect to such ratification were as follows:

 

For    Against    Abstain    Broker
Non-Votes
109,564,727    56,762    42,951    — 

 

  (c)

The stockholders of the Company approved the advisory vote on the compensation of the Company’s named executive officers. The results of the stockholders’ non-binding advisory vote with respect to the compensation paid to the Company’s named executive officers were as follows:

 

For    Against    Abstain    Broker
Non-Votes
93,573,357    10,540,010    44,708    5,506,364

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Apellis Pharmaceuticals, Inc.
Date: June 5, 2024     By:  

/s/ Timothy Sullivan

      Timothy Sullivan
      Chief Financial Officer
v3.24.1.1.u2
Document and Entity Information
Jun. 05, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001492422
Document Type 8-K
Document Period End Date Jun. 05, 2024
Entity Registrant Name Apellis Pharmaceuticals, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-38276
Entity Tax Identification Number 27-1537290
Entity Address, Address Line One 100 Fifth Avenue
Entity Address, City or Town Waltham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02451
City Area Code (617)
Local Phone Number 977-5700
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock
Trading Symbol APLS
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Apellis Pharmaceuticals Charts.
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Apellis Pharmaceuticals Charts.